This is the authors' abstract. We don't add key points for this paper.
CRISPR-Cas systems have immense biotechnological utility. A recent study reveals the potential of the Cpf1 nuclease to complement and extend the existing CRISPR-Cas9 genome-editing tools.
No takes yet. Share an insight, caveat, or question.
Fagerlund et al. (2015) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: